Other substances

Ibuprofen

A nonsteroidal anti-inflammatory drug.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Ibuprofen on PubChem

Marketed as

Sold under multiple prescription and over the counter product brands.

CC(C)CC1=CC=C(C=C1)C(C)C(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease 3CLpro Small molecule In silico	in silico	3.22	Both enantiomers (R(−) and (S(+)) were predicted to bind the SARS-CoV-2 3C-like protease.	Jan/18/2021

AI-suggested references

Link	Publication date
Potential Effects of Ibuprofen, Remdesivir and Omeprazole on Dexamethasone Metabolism in Control Sprague Dawley Male Rat Liver Microsomes (Drugs Often Used Together Alongside COVID-19 Treatment).	Mar/30/2022
Analgesic benefit of metamizole and ibuprofen vs. either medication alone: a randomized clinical trial.	Apr/13/2022
Nebulization with alkaline hipertonic ibuprofen induces a rapid increase in platelets circulating in COVID-19 patients but not in healthy subjects.	Sep/16/2021
Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors	Sep/24/2021
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection	Oct/26/2021
Ibuprofen use and clinical outcomes in COVID-19 patients	Jun/12/2020
SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets.	Feb/18/2021
In silico study of potential antiviral activity of copper(II) complexes with non-steroidal anti-inflammatory drugs on various SARS-CoV-2 target proteins	Mar/18/2022
Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection	Jan/13/2021
Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.	Nov/06/2020
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program	Dec/01/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04334629	LIBERATE Trial in COVID-19	Recruiting	Phase 4	May/26/2020	Sep/25/2021
Alternative id - 282009 Interventions - Drug: Ibuprofen Study type - Interventional Study results - No Results Available Locations - Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 230 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Disease progression\|Time to mechanical ventilation\|Overall survival\|Reduction in proportion of patients who require ventilation\|Reduction in length of Critical Care stay\|Reduction in length of Hospital stay\|Modulation of serum pro- and anti-inflammatory cytokines\|Reduction in duration of ventilation\|Increase in ventilator-free days
NCT04382768	Inhaled Ibuprofen to Treat COVID-19	Recruiting	Not Applicable	May/01/2020	Jan/01/2021
Alternative id - DNL000004 Interventions - Drug: Inhaled Hypertonic ibuprofen Study type - Interventional Study results - No Results Available Locations - Centro de Excelencia en Productos y Procesos Córdoba, Córdoba, Argentina Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen.\|Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen.\|Chage in length of Hospital stay\|Chage in duration of ventilation\|Chage in length of Critical Care stay\|Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28.\|Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28.\|Time from first dose to conversion to normal or mild pneumonia\|Antibiotic requirement\|Glucocorticoids requirement\|Incidence of adverse event\|Incidence of serious adverse event\|Number of deaths from any cause at 28 days\|Lymphocyte count
NCT04383899	Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019	Withdrawn		Sep/30/2020	Nov/30/2020
Alternative id - CHUBX 2020/13 Interventions - Other: Questionnaire Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 0 Age - Child, Adult, Older Adult Outcome measures - Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.\|Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.\|Describe other patient characteristics with worse infection in COVID-19 patients in France.\|Quantify other patient characteristics with worse infection in COVID-19 patients in France.

Export (.csv)